MTM(SH:688029)2022-04-25 16:00Financial Performance - The company's revenue for Q1 2022 was RMB 442.69 million, representing a year-on-year increase of 12.50%[2] - Net profit attributable to shareholders decreased by 35.12% to RMB 43.37 million compared to the same period last year[3] - The net profit for Q1 2022 was CNY 45,515,035.82, a decrease of 33.7% compared to CNY 68,602,707.57 in Q1 2021[20] - The total profit for Q1 2022 was CNY 51,769,026.44, down 38.0% from CNY 83,464,682.36 in the same period last year[20] - Basic earnings per share decreased by 35.31% to RMB 0.3243, while diluted earnings per share fell by 36.08% to RMB 0.3204[3][6] - The basic earnings per share for Q1 2022 was CNY 0.3243, down 35.4% from CNY 0.5013 in Q1 2021[21] - The total comprehensive income for Q1 2022 was CNY 46,810,970.95, a decrease of 31.3% from CNY 68,157,770.33 in Q1 2021[21] Cash Flow and Assets - The net cash flow from operating activities was negative RMB 23.32 million, a decrease of 140.76% year-on-year[3] - The cash flow from operating activities in Q1 2022 was negative at CNY -23,322,108.23, compared to a positive CNY 57,223,313.91 in Q1 2021[23] - The company reported cash and cash equivalents of ¥845,290,400.25 as of March 31, 2022, down from ¥1,163,460,843.93 on December 31, 2021, representing a decrease of approximately 27.3%[15] - The company’s cash and cash equivalents at the end of Q1 2022 were CNY 845,290,400.25, compared to CNY 603,316,173.81 at the end of Q1 2021[24] - The total assets at the end of the reporting period were RMB 3.59 billion, a decrease of 1.12% from the end of the previous year[3] - The total assets as of Q1 2022 were CNY 3,591,238,587.61, slightly down from CNY 3,631,746,826.61 in the previous year[18] Operating Performance - Domestic sales revenue reached RMB 276 million, up 21.77% year-on-year, driven by new visual products generating RMB 45.58 million in sales[3] - International sales revenue was RMB 166 million, remaining flat year-on-year, with a 13.86% decrease in Europe due to geopolitical conflicts[3] - Revenue from sales of goods and services in Q1 2022 reached CNY 557,562,689.05, an increase of 44.1% compared to CNY 386,793,735.99 in Q1 2021[22] - Total operating revenue for Q1 2022 was CNY 442,690,227.21, an increase of 12.5% compared to CNY 393,518,815.47 in Q1 2021[19] - Total operating costs for Q1 2022 were CNY 393,863,563.17, up from CNY 318,764,464.08 in Q1 2021, reflecting a 23.5% increase[19] Research and Development - R&D investment totaled RMB 40.61 million, an increase of 47.33% year-on-year, accounting for 9.17% of revenue, up 2.17 percentage points[3][8] - Research and development expenses for Q1 2022 amounted to CNY 40,606,208.52, a significant increase from CNY 27,561,258.83 in Q1 2021, representing a 47.4% rise[19] Shareholder Information - The top shareholder, Shanghai Gao Yi Asset Management, holds 2,150,000 shares, representing a significant stake in the company[11] - The company has not disclosed any related party transactions among its top shareholders[12] - The company has not engaged in any financing or securities lending activities among its top shareholders[12] Market Expansion and Product Development - The company obtained 21 new medical device registrations during the reporting period, including products like the bronchial occlusion catheter and disposable sterile pancreaticobiliary tissue sampling forceps[13] - The company expanded its product offerings with changes to existing medical devices, including the expansion of specifications for the disposable biopsy needle[14] - The company is actively pursuing market expansion with new product registrations in regions such as Singapore, Thailand, and Japan[13] - The company plans to expand its market presence and invest in new product development to drive future growth[19] - The company has identified strategic opportunities for mergers and acquisitions to enhance its competitive position in the market[19] Financial Health - The total liabilities for Q1 2022 were CNY 538,449,701.35, a decrease from CNY 641,444,869.77 in Q1 2021, indicating a reduction of 16.1%[17] - The total equity attributable to shareholders increased to CNY 3,003,330,445.77 in Q1 2022 from CNY 2,943,321,990.43 in Q1 2021, marking a growth of 2.0%[18] - The weighted average return on equity was 1.44%, a decrease of 1.07 percentage points year-on-year[3] - The company incurred share-based payment expenses of RMB 15.68 million due to the implementation of the 2020 restricted stock incentive plan[3]